National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 49215 [2017-22967]

Download as PDF Federal Register / Vol. 82, No. 204 / Tuesday, October 24, 2017 / Notices 49215 TABLE 1—Continued Application No. ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA 085720 085721 085778 086096 086189 086598 086795 087183 087296 087521 087772 087979 088030 089042 ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ Drug Meprobamate Tablets USP, 200 mg ........................................................ Meprobamate Tablets USP, 400 mg ........................................................ Hydroxyzine HCl Injection USP, 25 mg/mL .............................................. Chlorpheniramine Maleate Injection USP, 10 mg/mL ............................... Ergoloid Mesylates Sublingual Tablets USP, 0.5 mg ............................... Nandrolone Decanoate Injection USP, 100 mg/mL .................................. Chlorothiazide Tablets USP, 250 mg ........................................................ Ergoloid Mesylates Sublingual Tablets USP, 1 mg .................................. Chlorthalidone Tablets USP, 25 mg ......................................................... Chlorthalidone Tablets USP, 50 mg ......................................................... Prednisone Tablets USP, 50 mg .............................................................. Chloroquine Phosphate Tablets USP, EQ 150 mg base ......................... Chloroquine Phosphate Tablets USP, EQ 300 mg base ......................... Procainamide HCl Extended-Release Tablets USP, 750 mg ................... Therefore, approval of the applications listed in table 1, and all amendments and supplements thereto, is hereby withdrawn as of November 24, 2017. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in table 1 that are in inventory on the date that this notice becomes effective (see the DATES section) may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: October 18, 2017. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2017–23046 Filed 10–23–17; 8:45 am] BILLING CODE 4164–01–P BILLING CODE 4140–01–P asabaliauskas on DSKBBXCHB2PROD with NOTICES National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which Jkt 244001 Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44). Date: November 17, 2017. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Vasundhara Varthakavi, Ph.D., DVM, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3E70, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5020, varthakaviv@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) [FR Doc. 2017–22967 Filed 10–23–17; 8:45 am] National Institutes of Health 17:47 Oct 23, 2017 would constitute a clearly unwarranted invasion of personal privacy. Dated: October 18, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate Sep<11>2014 Applicant DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; International Research Ethics Training. Date: November 16, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Karin F. Helmers, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 20892, (301) 254– 9975, helmersk@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR16–121 Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01). Date: November 16, 2017. Time: 12:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Raul Rojas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 451–6319, rojasr@ mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Macromolecular Structure and Function. Date: November 20, 2017. Time: 1:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: C-L Albert Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of E:\FR\FM\24OCN1.SGM 24OCN1

Agencies

[Federal Register Volume 82, Number 204 (Tuesday, October 24, 2017)]
[Notices]
[Page 49215]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22967]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial 
Implementation Cooperative Agreement (U44).
    Date: November 17, 2017.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Vasundhara Varthakavi, Ph.D., DVM, Scientific 
Review Officer, Scientific Review Program, Division of Extramural 
Activities, Room 3E70, National Institutes of Health, NIAID, 5601 
Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5020, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: October 18, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-22967 Filed 10-23-17; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.